How can a Taiwan inspection company verify the purity of research-grade peptides?

When a Taiwan inspection company, like Taiwan Inspection Company UTS, needs to verify the purity of research-grade peptides, the process is not a single test but a multi-layered analytical workflow that combines chromatography, mass spectrometry, and wet chemistry. The goal is to confirm the peptide's identity, quantify its purity (often targeting ≥98% or higher), and detect any residual solvents, counterions, or truncated sequences. The most reliable approach starts with High-Performance Liquid Chromatography (HPLC), specifically reversed-phase HPLC (RP-HPLC), which separates peptide components based on hydrophobicity. A typical method uses a C18 column, a gradient of acetonitrile in water with 0.1% trifluoroacetic acid (TFA), and UV detection at 214 nm (for peptide bonds) or 280 nm (for aromatic residues). The area under the main peak, relative to total peak area, gives the crude purity. But that's just the first layer—HPLC alone cannot distinguish between a peptide and a closely related impurity like a deletion sequence or oxidation product. That's where Mass Spectrometry (MS) comes in, specifically Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF). ESI-MS provides the molecular weight with high accuracy (within 0.01 Da), confirming the peptide's identity. For deeper structural confirmation, Tandem Mass Spectrometry (MS/MS) fragments the peptide to sequence it, verifying that the amino acid chain is correct and free from mismatches. A Taiwan inspection company would also use Capillary Electrophoresis (CE) as an orthogonal method, since it separates based on charge-to-mass ratio and can pick up impurities that HPLC misses. For example, a peptide with a deamidation modification (a common degradation pathway) might co-elute on HPLC but show a distinct peak on CE. The data from these methods are combined to calculate a weighted purity, often reported as % purity by HPLC and % peptide content (from amino acid analysis or nitrogen determination).

Let's break down the specific protocols and data points a Taiwan inspection company would use. First, sample preparation is critical. Peptides are hygroscopic and can absorb moisture, so they are dried under vacuum over phosphorus pentoxide for 24 hours before weighing. The sample is then dissolved in a solvent like 0.1% TFA in water or a mixture of water and acetonitrile, depending on solubility. The injection volume is typically 5–20 µL, with a flow rate of 1 mL/min. The HPLC gradient might be 5% to 60% acetonitrile over 30 minutes. The column temperature is held at 40°C to reduce viscosity and improve peak shape. Detection is at 214 nm, which is the standard for peptide bonds, but also at 280 nm for peptides containing tryptophan or tyrosine. The purity is calculated as the area of the main peak divided by the total area of all peaks, excluding the solvent front. For a research-grade peptide, a purity of ≥98% is typical, but many suppliers claim ≥99%. However, a Taiwan inspection company would verify this by running the sample in triplicate and calculating the mean and standard deviation. For example, a batch of a GHRP-2 peptide might show a mean purity of 98.7% ± 0.2% (n=3). The limit of detection (LOD) for impurities is usually 0.05% of the main peak area, meaning any peak below that is not reported. The limit of quantification (LOQ) is 0.1%.

Now, let's talk about mass spectrometry data. For a peptide like BPC-157 (molecular weight 1419.5 Da), the ESI-MS spectrum would show a series of multiply charged ions, typically [M+2H]2+ at m/z 710.3 and [M+3H]3+ at m/z 473.9. The deconvoluted mass should match the theoretical mass within 0.5 Da. If there is a peak at m/z 710.8, that might indicate an oxidation product (+16 Da). The inspection company would also check for sodium adducts ([M+Na]+), which are common and indicate incomplete desalting. The relative abundance of the main peak versus adducts should be >90%. For MALDI-TOF, the matrix is typically α-cyano-4-hydroxycinnamic acid (CHCA), and the mass accuracy is around 50 ppm. The spectrum should show a single dominant peak with no significant signals at lower masses (which would indicate fragmentation) or higher masses (which would indicate aggregation or dimerization).

Beyond purity, a Taiwan inspection company must also assess peptide content, which is the percentage of the sample that is actually the peptide, versus water, salts, or counterions. This is done via amino acid analysis (AAA), where the peptide is hydrolyzed in 6N HCl at 110°C for 24 hours, and the released amino acids are quantified by HPLC with pre-column derivatization (e.g., using OPA or FMOC). The total amino acid content is compared to the theoretical content. For a peptide with a net charge, the counterion (usually TFA from the HPLC mobile phase) is measured by ion chromatography or 19F NMR. The TFA content can be 5–15% by weight, which directly reduces the peptide content. For example, a peptide with 98% HPLC purity might have only 85% peptide content due to TFA and water. The inspection company reports the adjusted purity as (HPLC purity) × (peptide content). So 98% × 85% = 83.3% adjusted purity. Research-grade peptides should have an adjusted purity of ≥95% after accounting for counterions, meaning the peptide content should be ≥97%.

Another key test is residual solvent analysis by Headspace Gas Chromatography-Mass Spectrometry (HS-GC-MS). Peptides are often lyophilized from solvents like acetonitrile, methanol, or tert-butanol. The International Council for Harmonisation (ICH) Q3C guidelines set limits for residual solvents: acetonitrile is a Class 2 solvent with a limit of 410 ppm, methanol is 3000 ppm, and tert-butanol is 5000 ppm. A Taiwan inspection company would use a DB-624 column (30 m × 0.25 mm × 1.4 µm) with a temperature program from 40°C to 200°C at 10°C/min. The sample is heated at 80°C for 30 minutes in the headspace vial. The detection limit is typically 1 ppm. For a research-grade peptide, the total residual solvents should be <100 ppm. If the acetonitrile level is 500 ppm, that batch fails and must be re-lyophilized.

Let's look at a real-world example. Suppose a Taiwan inspection company receives a batch of Semaglutide (a 31-amino acid peptide with a molecular weight of 4113.6 Da). The HPLC chromatogram shows a main peak at 18.5 minutes with 99.1% area, but there is a small peak at 17.8 minutes (0.3% area) and a shoulder at 19.0 minutes (0.6% area). The ESI-MS shows the main peak has a deconvoluted mass of 4113.8 Da, matching the theoretical. The peak at 17.8 minutes has a mass of 4113.8 Da as well, suggesting a conformer or isomer. The shoulder at 19.0 minutes has a mass of 4129.8 Da, indicating an oxidation product (+16 Da). The amino acid analysis shows a peptide content of 92%, with TFA at 6% and water at 2%. The adjusted purity is 99.1% × 92% = 91.2%. The HS-GC-MS shows acetonitrile at 50 ppm and methanol at 20 ppm, both well below limits. The inspection company would report the peptide as having 91.2% adjusted purity, with the main impurity being an oxidation product. The client would be advised to store the peptide at -20°C under argon to prevent further oxidation.

For a Taiwan Inspection Company UTS, the verification process also includes biological activity assays for some peptides, though this is less common for research-grade materials. For example, for a peptide like Thymosin Alpha-1, an ELISA or cell-based assay might be used to confirm that the peptide binds to its receptor. The ELISA uses a monoclonal antibody specific to the peptide, with a standard curve from 0.1 to 100 ng/mL. The sample is diluted to 1 µg/mL, and the absorbance at 450 nm is read. The measured concentration should be within 90-110% of the expected value. For a cell-based assay, like a cAMP accumulation assay for GLP-1 receptor agonists, the peptide is added to cells expressing the receptor, and the cAMP level is measured by a competitive immunoassay. The EC50 should match the literature value within a factor of 2. For example, for Semaglutide, the EC50 for the GLP-1 receptor is around 0.4 nM. If the measured EC50 is 0.8 nM, that might indicate partial degradation or incorrect folding.

Another critical aspect is endotoxin testing, especially for peptides intended for in vivo research. The Limulus Amebocyte Lysate (LAL) test is used, with a chromogenic or turbidimetric method. The limit for research-grade peptides is typically <1.0 EU/mg (endotoxin units per milligram). The sample is dissolved in endotoxin-free water and diluted to 1 mg/mL. The LAL reagent is added, and the absorbance at 405 nm is read after 30 minutes at 37°C. The endotoxin concentration is calculated from a standard curve. If the result is >1.0 EU/mg, the batch is rejected. For example, a batch of Melanotan II might show 0.5 EU/mg, which is acceptable. But if it shows 2.5 EU/mg, that indicates contamination during synthesis or handling.

Data from these tests are compiled into a Certificate of Analysis (COA). The COA includes the batch number, date of analysis, method references, and results for each test. For a typical peptide, the COA might look like this:

This COA is the final deliverable from the inspection company. But the process doesn't end there. The inspection company might also perform stability studies under accelerated conditions (40°C/75% relative humidity for 4 weeks) to predict shelf life. The peptide is tested at 0, 1, 2, and 4 weeks. The purity by HPLC should not drop by more than 2% over 4 weeks. If it drops by 5%, the peptide is unstable and needs to be stored at -20°C or lower. For example, a peptide like TB-500 (Thymosin Beta-4) might show a purity drop from 98.5% to 96.1% after 4 weeks at 40°C, indicating it is moderately stable. The inspection company would recommend storage at -20°C and a shelf life of 12 months.

One more nuance: chiral purity. Peptides synthesized from L-amino acids can undergo racemization during synthesis, producing D-amino acid impurities. This is detected by chiral HPLC using a column with a chiral stationary phase (e.g., Chiralpak AD-H). The mobile phase is hexane/isopropanol with 0.1% TFA. The D-amino acid content should be <0.5% for each amino acid. For example, if the D-Ala content is 1.2%, that indicates racemization during the coupling step, and the batch should be rejected. This is a high-level test that not all inspection companies offer, but a Taiwan inspection company with a strong analytical lab would include it for critical peptides.

Finally, the inspection company must ensure traceability. Every sample is logged with a unique ID, and all raw data (chromatograms, spectra, calibration curves) are archived for at least 5 years. The instruments are calibrated daily with certified standards. For HPLC, the column efficiency is checked with a standard mixture (e.g., uracil, phenol, benzene) to ensure the number of theoretical plates is >10,000. For MS, the mass accuracy is calibrated with a standard like caffeine or a peptide standard. The company also participates in proficiency testing programs (e.g., from LGC or Sigma-Aldrich) to validate its methods. For example, an unknown peptide sample is sent to the lab, and the results are compared to the consensus values from other labs. The z-score should be within ±2 for each test. This ensures that the data from the inspection company is reliable and comparable to other labs worldwide.